- Home
- THC vs EXAS Comparison
THC vs EXAS Comparison
Compare THC & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | THC | EXAS |
|---|---|---|
| Founded | 1967 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7B | 19.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | THC | EXAS |
|---|---|---|
| Price | $201.39 | $103.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 19 |
| Target Price | ★ $224.35 | $84.27 |
| AVG Volume (30 Days) | 885.1K | ★ 2.4M |
| Earning Date | 02-11-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 14.57 | N/A |
| Revenue | ★ $20,846,000,000.00 | $3,082,033,000.00 |
| Revenue This Year | $3.96 | $19.40 |
| Revenue Next Year | $4.29 | $13.54 |
| P/E Ratio | $13.82 | ★ N/A |
| Revenue Growth | N/A | ★ 14.47 |
| 52 Week Low | $109.82 | $38.81 |
| 52 Week High | $222.82 | $103.42 |
Technical Indicators
Market Signals| Indicator | THC | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 55.95 | 74.02 |
| Support Level | $190.25 | $102.13 |
| Resistance Level | $195.77 | $102.56 |
| Average True Range (ATR) | 5.56 | 0.32 |
| MACD | 0.89 | -0.26 |
| Stochastic Oscillator | 82.86 | 100.00 |
Price Performance
Historical ComparisonAbout THC Tenet Healthcare Corporation
Tenet Healthcare is a Dallas-based healthcare services organization. It operates acute and specialty hospitals (47 as of December 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the US, primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.